Pharmaceutical and biotechnology companies buy biosimulation in two forms: software they license and run internally, or a modeling project carried out for them by a specialist provider or a contract research organization. Contract research organizations, academic research institutions and regulatory authorities also buy into this market, the last group typically reviewing simulation-supported submissions built by others, not producing them itself. What all these buyers are paying for is prediction: computational methods, among them physiologically based pharmacokinetic and quantitative systems pharmacology modeling, that forecast how a drug candidate will behave in the body before physical testing begins, or alongside it.
Contrive Datum Insights has published "Biosimulation Market Size, Share & Industry Analysis, By Product (Software, Services, In-house Services, Contract Services), Application (Drug Development, Drug Discovery, Others), Delivery model (Subscription Models, Ownership Models), End-use (Pharmaceutical & Biotechnology Companies, CRO, Regulatory Authorities, Academic Research Institutions), Therapeutic area (Oncology, Infectious Diseases, Cardiovascular Diseases, Others), and Regional Forecast, 2026-2034." The study puts the global market at USD 4.05 billion in 2025, rising to USD 4.72 billion in 2026 and USD 14.94 billion by 2034: a compound annual growth rate of 15.5% over the forecast period.
Where the Spending Goes
Software accounts for the largest share of buyer spending, 46% of 2025 revenue at USD 1.863 billion, though its share narrows to 42% by 2034 as other lines grow faster around it. Contract Services, the outsourced-modeling line, expands at 20.27% a year, taking its share of revenue from 18% to 26% and its value from USD 0.729 billion to USD 3.884 billion. Buyers are also shifting how they pay for access: Subscription Models already account for 55% of 2025 revenue (USD 2.228 billion), ahead of one-time ownership licensing.
By application, Drug Development draws the largest budgets, 58% of 2025 revenue at USD 2.349 billion, while spending on Drug Discovery grows fastest, at 17.13% a year. Pharmaceutical and biotechnology companies remain the dominant end-use buyer, 62% of 2025 revenue at USD 2.511 billion, but contract research organizations increase their purchases fastest, at 17.77%. Among therapeutic areas, oncology commands the single largest slice of spending: 34% of 2025 revenue, worth USD 1.377 billion.
Regionally, North America accounts for 42% of 2025 revenue (USD 1.701 billion) and is projected to reach USD 5.677 billion by 2034; the United States alone represents USD 1.446 billion of that 2025 total, 35.7% of global revenue. Asia Pacific's share climbs from 22% to 27% over the same period, with revenue rising from USD 0.891 billion to USD 4.034 billion. The Middle East and Africa stays the smallest region throughout, moving only from 4% to 5% of global revenue.
The report attributes much of this trajectory to widening regulatory acceptance of model-informed drug development, rated as the highest-impact factor in the forecast. Under a scenario where that acceptance broadens faster and enterprise buyers convert to subscription licensing sooner, 2034 revenue could reach USD 17.93 billion instead of the USD 14.94 billion base case; under a slower scenario, with budget approvals delayed, it could fall short at USD 12.25 billion. The three groups named at the outset, drug developers licensing software, CROs and providers running outsourced projects, and regulators reading the submissions those projects support, are the ones whose purchasing decisions will settle which of the three outcomes the market actually reaches.
The report segments the market across five axes: product, application, delivery model, end-use and therapeutic area, with revenue and a growth rate for every line in every year from 2020 to 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.